Multiple major broad-based index rebalancings will take place this Friday, adding leading solar and semiconductor stocks, affecting ETF assets totaling nearly RMB 700 billion.

① The adjustments to major broad-based indices, including the CSI 300 and CSI A500, will take effect after the market closes this Friday, with the total assets under management of all ETFs tracking these indices amounting to RMB 693.452 billion; ② Multiple indices have seen an increase in their 'technology content,' as key companies in sectors such as memory storage, optical communications, wafer foundry, and photonic chips have been added to several broad-based indices.

cls.cnJun 9 17:50

Changchun High-Tech Industry Gets US FDA Nod for Cancer Drug Trial

MT NewswiresJun 2 16:16

Express News | Changchun High-tech: Subsidiary GenSci's Tablet 145 Receives FDA Approval to Initiate Clinical Trials

BreakingsJun 1 16:55

Express News | Changchun High-Tech: The marketing application for Leuprolide Acetate Injection (6M) has been accepted.

BreakingsMay 29 17:03

Changchun High & New Technology Industries (Group) Co., Ltd. (000661.SZ): The application for clinical trials of GenSci144 tablets, developed by Jin Sai Pharmaceutical, has been approved for domestic drug registration.

Changchun High & New Technology Industries (Group) Co., Ltd. (SZSE: 000661) announced that its subsidiary, Changchun GenSci Pharmaceutical Co., Ltd. (hereinafter referred to as "GenSci Pharmaceutical"), has recently received a "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, approving GenSci Pharmaceutical's application for clinical trials of GenSci144 tablets as a domestically manufactured drug.

Zhitong FinanceMay 26 16:06

Sustained net capital inflows! The underlying indices of BioPharma ETF Tianhong (159859) and Innovative Drugs ETF Tianhong (517380) rose more than 2.5%, with institutions noting that China's innovative drug sector is demonstrating increasing global value.

Gelonghui, May 21 | The innovative pharmaceuticals sector rose, with Zhaoyan New Drug hitting its daily trading limit, driving the benchmark index of the Tianhong Biopharmaceutical ETF (159859) up 2.71% and that of the Tianhong Innovative Pharmaceuticals ETF (517380) up 2.57%. Capital continued to flow net positively into pharmaceutical-related ETFs. The Tianhong Biopharmaceutical ETF (159859) recorded net inflows of RMB 510 million over the past 20 trading days, while the Tianhong Innovative Pharmaceuticals ETF (517380) saw net inflows of RMB 758.8 million during the same period. The Tianhong Biopharmaceutical ETF (159859) tracks the Guozheng Biopharmaceutical Index, covering a broader range of healthcare and pharmaceutical sectors.

Gelonghui FinanceMay 21 10:40